The impact of the clinical trial of venetoclax (ABT-199) and obinutuzumab in CLL
Highlights of ASH in CLL
John Gribben et al.
SGN-CD33A with hypomethylating therapy produces high remission rates among older AML patients
What is the potential of daratumumab in combination therapy for myeloma?
The importance of targeting proliferating and quiescent cells in CLL